INTRODUCTION
Development of a safe, effective and affordable vaccine represents the best hope for controlling the spread and consequences of the hepatitis B virus (HBV) epidemic worldwide. Recent data have indicated that immunotherapeutic strategies stimulating both cellular and humoral immune responses to HBV antigens are essential to cure chronic HBV infection . In this regard, DNA-based vaccination appears a particularly pertinent approach for chronic hepatitis B treatment, since it has been well-documented to elicit durable humoral and cellmediated immunity including cytotoxic T lymphocytes (CTL) and cytokines in normal mice (Brazolot Millan et al., 1998; Oka et al., 2001) , HBV-Tg mice (Oka et al., 2001) , ducks (Le Guerhier et al., 2003) and chimpanzees (Davis et al., 1996) . It is a good candidate for immunization of non-responders to recombinant HBsAg vaccines and for therapeutic vaccination (Brazolot Millan et al., 1998) , providing a promising option for the development of subunit vaccines. In our previous study, intramuscular (i.m.) injection of plasmid DNA vectors encoding the middle envelope proteins could prevent experimental infection of tree shrews with HBV (Zhou et al., 2003) .
However, even at higher doses of DNA, human clinical trials of HBV DNA vaccine have only yielded much lower levels of immune responses than have been observed in small animals. Such a situation was also found with a human immunodeficiency virus (HIV) DNA vaccine (Tacket et al., 1999; Boyer et al., 2000) . Therefore, the potency of DNA 3These authors contributed equally to the manuscript.
vaccines must be increased to enable this technology for successful human application.
Mucosal vaccination generates systemic and local immunity. The most attractive route of mucosal immunization is oral, because of its high patient compliance, ease of administration and applicability to mass vaccination. Recently, various attempts have been made to demonstrate the efficacy of biodegradable and biocompatible microspheres as particulate delivery systems in order to induce systemic and local immune responses following oral immunization (O'Hagan & Singh, 2003) . A wide range of polymeric materials have been explored for their ability to enhance the immunogenicity of oral vaccines, such as poly(DL-lactide-co-glycolic acid) (PLGA) (Sharpe et al., 2003; Herrmann et al., 1999; Singh et al., 2001) , starch (Wikingsson & Sjoholm, 2002) , chitosan and other cationic polymers (Illum et al., 2001; Twaites et al., 2004) , since microparticles of less than 10 mm are readily taken up by intestinal M cells, macrophages and other professional antigen-presenting cells (APCs), leading to antigen presentation in regional inductive immune sites (Kim et al., 1999; Baras et al., 1999; Okada & Toguchi, 1995) . Of these, PLGA has already been approved as a component of a number of drug-delivery systems and has a long history of safe use in humans (Klencke et al., 2002; Okada & Toguchi, 1995) . More recently, it was shown that PLGAencapsulated plasmid DNA elicited systemic and mucosal antibodies to the encoded antigen, as well as CTL responses after oral delivery in non-primate and primate models (Kaneko et al., 2000; Sharpe et al., 2003; Herrmann et al., 1999; Singh et al., 2001) .
In this study, we evaluated the feasibility of using plasmid DNA encoding HBsAg encapsulated in PLGA microparticles to induce local and systemic HBsAg-specific immunity following single-dose oral immunization. The immunogenicity of encapsulated DNA administrated by the oral route was compared with naked DNA vaccine injected i.m. The potential advantages of encapsulated DNA vaccine over naked DNA vaccines are discussed.
METHODS
Plasmid construction. The small envelope gene of HBV was amplified by PCR from the HBV genome (adr subtype) obtained from a patient's serum positive for HBV and was cloned into the EcoRI/BamHI sites of plasmid vector pVAX1 (Invitrogen Life Technologies). The resultant plasmid, pVAX(S) was amplified in Escherichia coli, isolated by alkaline lysis and purified by double banding in equilibrium gradients. Endotoxin was removed by multiple Triton X-114 extractions. All plasmid preparations were found to contain fewer than 50 endotoxin units (mg purified DNA)
21 by the Limulus amoebocyte lysate assay.
Preparation of PLGA. DNA was microencapsulated in PLGA as described previously (Tinsley-Bown et al., 2000) . Briefly, solutions of two PLGA polymers, RG502 and RG503 (Boehringer Ingelheim), were mixed 50 : 50 in ethyl acetate (4 ml) and emulsified with 0?4 ml pVAX(S) (10 mg ml 21 ) in STE buffer (100 mM NaCl, 10 mM Tris/HCl, 1 mM EDTA, pH 8?0). This emulsion was added immediately to an 8 % aqueous polyvinyl alcohol solution (66 ml) preheated to 30 uC and emulsified, resulting in the formation of a water-in-oil-in-water emulsion. Microparticles were harvested by centrifugation, washed several times to remove the polyvinyl alcohol and residual solvent and finally lyophilized. A control formulation with the empty vector pVAX1 encapsulated into PLGA microparticles was similarly manufactured. For the phagocytosis experiment, PLGA-pVAX(S) microparticles containing encapsulated rhodamine B were prepared individually with a target load of 0?25 % (w/w) rhodamine in PLGA by the same process.
Microparticles were generated at least three times. DNA encapsulation ranged from 4?1 to 6?2 mg (mg microparticles) 21 for lab-scale batches. The products showed regular and spherical microsphere morphology, with particle sizes in the range 2-9 mm with a median diameter of 5?7 mm, as examined with a particle size analyser and by scanning electron microscopy.
Immunization. BALB/c mice were bred and cared for in the animal facilities of the Second Military Medical University, Shanghai. Only female mice, 6-8 weeks old at the start of vaccination, were used. The microparticle formulation was suspended in 7?5 % sodium bicarbonate solution in order to buffer gastric acid fluids. A single dose of oral administration was performed with pVAX(S) encapsulated into PLGA microparticles by using a 24-gauge feeding needle. The microparticle dose was 20 or 200 mg per mouse. In order to test the reproducibility of batches, these experiments were carried out three times with separately produced batches of microparticles. The control groups received 200 mg empty vector pVAX1 encapsulated into PLGA microparticles by the same route. Single-dose i.m. inoculation was performed with naked pVAX(S) (20 or 200 mg in 200 ml saline per mouse) in two other groups of mice, to which ketamine [100 mg (kg body weight) 21 ] had been administered by i.m. injection 3 days before. A 100 ml formulation was injected in the tibialis anterior and another 100 ml was injected in the hamstring in the two hind legs of each animal. Sera were collected by retro-orbital bleeding 4 weeks after the immunization.
Fecal washes were prepared from fecal samples as described previously (Staats et al., 1996) . Briefly, fresh fecal samples (100 mg) were mixed with 1 ml PBS, incubated at room temperature for 15 min, vortexed and centrifuged in a microcentrifuge for 10 min. Supernatants were collected and stored at 220 uC until assayed for antiHBsAg antibody.
Antibody responses induced by different DNA formulations.
HBsAg-specific total antibody and intestinal IgA were analysed by ELISA in serum or fecal washes from individual mice in each group with a commercial kit (SIIC KeHua Biotech Co. Ltd). Ninety-sixwell plates were incubated with rHBsAg in PBS. The solid phase was incubated at 4 uC with HBsAg-specific antibody followed by incubation with horseradish peroxidase (HRP)-conjugated HBsAg or antibodies specific for mouse IgA. Serum from animals immunized with empty vector encapsulated into microparticles was used as the negative control (blanks). Binding of antibodies was measured as A 450 after reaction of immune complexes with substrate for HRP. Total antibody in serum was converted to mIU by comparison with a serially diluted standard antibody (Centers for Disease Control and Prevention China), while HBsAg-specific IgA titres were evaluated by A 450 . Mean titres were calculated from at least three points of the linear portion of the titration curve.
Cell isolation. Mice were sacrificed 4 weeks post-immunization and spleens were removed aseptically. Splenocytes were purified on Ficoll-Paque cushions. Lymphocytes from gut-associated lymph tissue (GALT), including Peyer's patches and lamina propria, were dissociated into single cells by enzymic digestion as described by Polyanskaya et al. (2001) . Briefly, the large and small intestines were dissected from individual mice and the fecal material was flushed from the lumen. After the Peyer's patches were identified and removed from the intestinal wall, the intestines were opened longitudinally. Tissues were placed into 1 mM EDTA and incubated twice at 37 uC to remove the epithelial cell layer. To isolate lamina propria lymphocytes, tissues were cut into small pieces and incubated in medium containing 300 U collagenase type VIII ml 21 (Sigma) for 50 min at 37 uC with stirring. Cells were carefully removed by discontinuous gradient centrifugation containing 75 and 40 % Percoll (Sigma).
RNA isolation and RT-PCR. Lymphocytes were isolated from Peyer's patches and lamina propria from six mice in each group at 24 h or 14 days after oral immunization with PLGA-encapsulated plasmid DNA at 200 mg per mouse. The muscle at the site of inoculation (tibialis anterior) and the draining lymph nodes (popliteal) were removed from six mice in each group at parallel time points after i.m. injection of naked pVAX(S) at the same dose. The muscle, lymph nodes or lymphocytes of six mice in each group were pooled for extraction of total cellular RNA. Total cellular RNA was isolated using TRIZOL (Life Technologies) and further purified using RNasefree DNase (Qiagen). Single-stranded cDNA (1 mg) was primed with oligo(dT) and synthesized using the Promega reverse transcription system. Primers specific for the HBV HBsAg gene sequence were used to amplify a 675-bp product; mouse b-actin primers were used to amplify a 360-bp product which served as a positive control. RT-PCR products were analysed by electrophoresis on 1?5 % agarose gels containing ethidium bromide.
Confocal laser scanning microscopy. Lymphocytes were isolated and pooled from Peyer's patches of six mice in each group at 24 h or 14 days after oral immunization with PLGA-DNA at a dose of 200 mg per mouse. Lymphocytes were isolated and pooled from popliteal lymph nodes of six mice in each group at parallel time points after i.m. injection of naked DNA at the same dose. Surface staining was performed in freshly prepared FACS staining buffer (PBS, 0?5 % BSA) for 15 min on ice in the presence of saturating concentrations of PE-conjugated mAb against CD11c (Pharmingen) (2 mg in 100 ml). Subsequently, lymphocytes were washed and fixed for with 4 % formalin. For immunolabelling intracellular HBsAg, cells were stained with FITC-conjugated mAbs against HBsAg in freshly prepared permeabilization buffer (PBS, 0?2 % BSA, 0?2 % saponin) for 40 min. To block Fcc receptor binding, samples were supplemented with 1 mg purified rat anti-mouse CD16/CD32 mAb (PharMingen).
Lymphocytes were smeared onto carrier sheet glass covered with a glass slide. Cells were viewed with a Zeiss LSM 510 confocal microscope equipped with LSM 510 software version 2.02 and Ar/Kr (458 and 488 nm) and He/Ne (543 nm) lasers. The lens used was a PlanNeofluar oil lens.
Gamma interferon (IFN-c) production assays. Splenocytes and GALT lymphocytes from eight mice in each group were tested for cytokine responses to purified recombined HBsAg protein (10 mg ml
21
). The IFN-c assay was described previously (Meseda et al., 2002) . Supernatants were harvested after 72 h, when peak amounts of the cytokine could be measured. Supernatants from at least three separate wells were pooled and assayed for the presence of IFN-c by ELISA, using a commercial kit (Jingmei Biotech). A range of dilutions of purified recombinant mouse IFN-c was included as standards.
In vitro cytotoxicity assays.
Immunomagnetic enrichment of CD8
+ lymphocytes. Splenocytes and GALT lymphocytes from eight mice in each group were pooled and tested for the ability to generate CTLs at 4 weeks postimmunization. Immunomagnetic enrichment of CD8 + lymphocytes was performed by a magnetic-activated cell sorter (MACS; Miltenyi Biotec), using microbeads conjugated with rat anti-mouse CD8a mAb (Miltenyi Biotec) according to the manufacturer's instructions (http://www.miltenyibiotec.com/). The preparation yielded enriched CD8 + lymphocyte populations of approximately 95 %, as confirmed by FACS analysis.
HBsAg-expressing CT26 cells. CT26 cells, a murine colon carcinoma cell line (H-2d, BALB/c mice), were permanently transfected with plasmid pcDNA3-(S), comprising the paternal plasmid pcDNA3 (Invitrogen Life Technologies) and an inserted sequence encoding HBsAg, under continuous selective pressure with 400 mg G418 ml 21 (Gibco-BRL). G418-resistant and HBsAg-expressing clones designated CT26/S were selected and screened for by PCR amplification of the integrated gene and expression of HBsAg by ELISA in our previous work (Zhou et al., 2003) .
CTL response assays. Stable transfectant CT26/S cells were used to raise CTLs by in vitro stimulation of splenocytes from immunized mice of each group for 7 days. CTL effector cells (2610 5 ) were cocultured with the 2610 3 CT26 cells (transfected with the vector DNA without insert) or stable CT26/S transfectants as targets in 200 ml wells for 4 h. Specific cytolytic activity of CTLs was tested by a non-radioactive and colorimetric assay, an alternative to the 51 Cr-release assay for the quantification of cell death and cell lysis, based on the measurement of lactate dehydrogenase activity released from the cytosol of damaged cells into the supernatant with the Cytotoxicity detection kit (Roche). The procedure is described in the manufacturer's protocol (http://www.roche-applied-science.com/ pack-insert/1644793a.pdf). The percentage of lysis was calculated as described by Sharpe et al. (2003) .
Statistical analysis. The Kruskal-Wallis non-parametric rank sum test and Wilcoxon's matched pairs test were used to test the significance of differences in humoral and cellular immune responses. Analysis of variance (ANOVA) was also performed. Data were analysed using SAS 8.2 (SAS Institution Inc.). A P value <0?05 was considered significant.
RESULTS
PLGA-DNA microparticles phagocytosed into mouse monocyte macrophage cell line RAW 264.7 expressed HBsAg in vitro
The physical state of encapsulated DNA was examined following release into solution. Gel electrophoresis revealed a high proportion of the supercoiled form. To determine whether microparticles could be phagocytosed and to investigate expression of the encapsulated DNA within the cells, microparticles were added to monolayers of RAW 264.7 cells. As shown in Fig. 1 , the amount of phagocytosed PLGA-DNA microparticles in RAW 264.7 cells increased with the co-incubation time up to 8 h.
Following incubation for 72 h, HBsAg was detectable in RAW 264.7 cells containing phagocytosed PLGA-DNA microparticles by Western blot analysis (Fig. 2) and by ELISA with a mAb against HBsAg (data not shown).
PLGA-DNA microspheres prolonged the expression and presentation of target antigen in GALT from immunized mice Because antigen presentation is required to elicit an immune response, it was necessary to determine whether oral PLGA-encapsulated DNA microparticles direct DNA delivery to APCs in vivo by an RT-PCR detecting gene transcription in GALT (Peyer's patches and lamina propria). HBsAg-specific mRNA in the lymph nodes, or lymphocytes, as well as muscle at the site of inoculation, was analysed by RT-PCR in each group. As illustrated in Fig. 3 , HBs mRNA expression was detected in both the Peyer's patches and lamina propria at 24 h and 14 days post-immunization with oral PLGA-DNA microparticles (200 mg per mouse). In contrast, mRNA expression was observed in the muscle and popliteal lymph node of mice immunized with naked DNA at 24 h, but not at day 14 post-immunization. The control group of mice inoculated with PLGA-pVAX1 microparticles, processed at the same time as PLGA-pVAX(S)-immunized animals, served as negative controls and exhibited no RT-PCR products, indicating that sample cross-contamination was unlikely. We also performed control PCR-only (no RT) reactions to confirm that HBsAg sequence detection depended on RT activity and was not the result of plasmid DNA contamination in the RNA preparation (data not shown).
We localized APCs involved in the expression and presentation of gene-encoding antigen in draining lymph nodes of A 24-well plate was seeded with suspensions of the mouse monocyte macrophage cell line RAW 264.7 in DMEM containing 10 % FCS and 0?1 mg kanamycin ml "1 to give approximately 80 % confluence after overnight incubation. Plasmid DNA-PLGA microparticles containing encapsulated rhodamine were prepared as described in Methods. Microparticles were suspended and added to monolayers with encapsulated DNA at a concentration of 20 mg per well. After different incubation times, wells were washed to remove excess microparticles and fresh growth medium was added. Phagocytosis was observed and photographed using a digital camera linked to a fluorescence microscope. six mice in each group with confocal laser scanning microscopy by double immunolabelling with PE-conjugated mAb against CD11c
+ and FITC-conjugated mAb against HBsAg. Persistence of expressed and presented HBsAg was observed at superficial and intercellular sites of CD11c + lymphocytes of Peyer's patches in mice immunized with PLGA-DNA microparticles at 24 h and 14 days post-immunization, while it was detected in CD11c + lymphocytes from popliteal lymph nodes from the group of mice inoculated i.m. with naked DNA at 24 h, but not at day 14 post-inoculation (Fig. 4) . There was also no detection in CD11c + lymphocytes from Peyer's patches of mice at 24 h or 14 days after immunization with orally administered naked plasmid DNA at the same dose (data not shown). Our observations provided more direct evidence that sustained expression and presentation of target antigen took place in APCs from immunized animals, compared with other groups' efforts to localize APCs around the site where the encoded antigen protein was detectable after i.m. inoculation of DNA vaccine by immunohistochemical staining of CD11c + dendritic cells and antigen protein (Oka et al., 2001) .
Taken together, the results suggested that plasmid DNA encapsulated into PLGA microparticles can be substantially distributed to the lymph nodes after oral administration, partly explaining the systemic and local immunogenicity of orally administered plasmid DNA vaccines. Our observation that sustained expression and presentation of target antigen correlated with the prolonged transcription of plasmid DNA in GALT 14 days post-immunization demonstrated that PLGA-DNA microparticles prolonged the expression and presentation of HBsAg in APCs with CD11 + phenotype in draining lymph nodes of immunized mice.
Enhanced HBsAg-specific local and systemic humoral responses following oral immunization with PLGA-DNA Because DNA vaccines have most frequently been delivered either by i.m. injection of naked DNA plasmid or by particle bombardment of skin tissue, we first compared levels of HBsAg-specific immune responses in mice immunized i.m. or orally with naked or PLGA-encapsulated plasmid DNA encoding HBsAg at 4, 8, 12, 16 and 20 weeks postimmunization. HBsAg-specific total antibody responses were detectable at different times after single oral immunization of PLGA-encapsulated DNA (20 or 200 mg per mouse), with a peak response at week 12 (Fig. 5a ). The formulation of oral PLGA-DNA (20 mg per mouse) increased potency to levels almost equivalent to that induced by i.m. injection of naked DNA (200 mg per mouse) (P>0?05). A significantly higher level of specific antibody response was induced when the oral dose of PLGA-encapsulated DNA was increased to 200 mg per mouse. The peak titre was approximately twice as high as that induced by i.m. injection of naked DNA at the same dosage (P<0?001). Therefore, by two separate criteria, After 6 h at 37 6C, cells were washed three times to remove excess microparticles and fresh growth medium was added. Following incubation for 72 h, cell monolayers were lysed and analysed by Western blotting using a mAb to HBsAg. Empty vector pVAX1 DNA encapsulated in microparticles served as a negative control. Lanes: 1, lysate of cells phagocytosing PLGA-pVAX(S) microparticles; 2, PLGApVAX1 microparticles; 3, purified recombined HBsAg; M, markers. increase in titre and decrease in DNA dose, PLGA formulation of DNA greatly increased HBV HBsAg DNA vaccine potency.
In subsequent studies, we analysed induction of intestinal HBsAg-specific IgA responses by immunization with naked or PLGA-encapsulated DNA. As shown in Fig. 5(b) , significant production of fecal IgA was detected in mice vaccinated by PLGA-pVAX(S) at 4, 8, 12 and 16 weeks, consistent with the antigen expressed in GALT described above, suggesting that a mucosal antibody response had been induced. In contrast, mucosal IgA responses were not detected in stools of mice injected i.m. with the naked DNA. Finally, no total antibody or IgA response was observed when PLGA-pVAX1 microparticles were used. Thus, oral immunizations with PLGA-DNA expressing HBsAg induced specific local and systemic humoral responses.
Enhanced HBsAg-specific local and systemic IFN-c production following oral immunization with PLGA-DNA It is accepted that strong antibody responses are important for clearing HBV and protection against HBV infection. There is also increasing evidence to show that the Th1 cell, CTL response to HBV and the associated antiviral cytokines (IFN-c, TNF-a, IL2) developed may play a key role in virus resolution during natural infection Rico et al., 2001) . The ability of PLGA microspheres containing HBsAg-encoding plasmid DNA to facilitate cellular uptake by the intestinal epithelium and APCs prompted us to analyse whether this delivery system induces cellular immunity in local and systemic lymphoid tissues. The production of IFN-c released from splenocytes and GALT in immunized mice after restimulation with purified rHBsAg in vitro was measured. Results representative of immunized mice observed by confocal laser scanning microscopy. Lymphocytes were isolated and pooled from Peyer's patches of six mice in each group at 24 h or 14 days after oral immunization with PLGA-encapsulated plasmid DNA at 200 mg per mouse. Lymphocytes were isolated and pooled from popliteal lymph nodes of six mice in each group at parallel time points after i.m. injection of naked DNA at the same dose. Surface staining was performed in the presence of saturating concentrations of PE-conjugated mAb against CD11c (red). Subsequently, lymphocytes were fixed with 4 % formalin and stained with FITC-conjugated mAb against HBsAg in permeabilization buffer to immunolabel membranous or intracellular HBsAg presented or expressed (green). Lymphocytes were smeared onto carrier sheet glass and viewed by confocal laser scanning microscopy.
three separate experiments are shown in Fig. 6 . A significant trend towards enhanced IFN-c responses was observed in groups of mice immunized with pVAX(S) encapsulated in microspheres (20 or 200 mg per mouse), compared with the response elicited by i.m. naked pVAX(S) injection at the same dose (Fig. 6) . The amount of IFN-c produced by splenocytes from mice immunized with encapsulated pVAX(S) (200 mg per mouse) [PLGA-pVAX(S), 1980 pg per 10 6 splenocytes] was approximately twice that produced by cells from mice immunized with the same amount of naked pVAX(S) (P<0?001).
Consistent with the mucosal IgA response, induction of IFN-c responses to HBsAg was detected only in GALT derived from mice immunized orally with PLGA-DNA encoding HBsAg. In contrast, the production of IFN-c in HBsAg-stimulated cultures established from lamina propria and Peyer's patches of mice immunized i.m. with naked plasmid DNA was at a background level (Fig. 6) . Cultures tested positive for IFN-c only when the mice had been immunized and the cultured cells were restimulated with HBsAg. Non-stimulated cells did not secrete IFN-c (data not shown).
PLGA-DNA microspheres facilitated HBsAgspecific local and systemic CTL responses
Since previous studies demonstrated that intragastric administration of plasmid encapsulated in PLGA microparticles could prime specific CTLs (Kaneko et al., 2000; Sharpe et al., 2003; Herrmann et al., 1999) , we analysed HBsAg-specific CTL responses of CD8 + lymphocytes isolated from spleen, lamina propria and Peyer's patches of mice in each group by immunomagnetic enrichment after oral and i.m. immunizations. Stable transfectant CT26/S cells expressing HBsAg were used as target cells to raise CTLs by in vitro stimulation of splenocytes or lymphocytes from immunized mice of each group for 7 days. No HBsAg-specific CTL activities of splenocytes were detectable at an effector : target cell ratio (E : T) of 100 : 1 in mice after i.m. immunization of naked DNA at a dose of 20 mg per mouse. A CTL response of splenocytes was detectable with a low specific lysis of 24 % at the same ratio in mice after a single i.m. inoculation of naked DNA at 200 mg per mouse, almost equivalent to that elicited in mice immunized by single-dose oral administration of PLGA-DNA (20 mg per mouse). Increased-dose oral administration of PLGA-DNA (200 mg per mouse) markedly enhanced the CTL response of splenocytes, with 43 % specific lysis at the same E : T ratio, which was approximately twice that elicited by immunization with naked DNA at the same dose (P<0?05) (Fig. 7) .
Mucosal CTL responses induced by orally delivered PLGA-DNA microparticles (200 mg per mouse) were significantly stronger than those measured in cultures established from lamina propria and Peyer's patches after i.m. immunization with naked DNA at the same dose, which was at a background level (P<0?001) (Fig. 7) .
The CTL activity was HBsAg specific, since mice immunized with PLGA-pVAX1 did not induce any detectable HBsAg-specific lysis and no CTL activity was observed in any of the groups of mice when parental CT26 cells were used as target cells (data not shown). Results obtained from three similar experiments were comparable.
DISCUSSION
The mucosa of the gastrointestinal tract, some 400 m 2 of surface area in adulthood (Miller et al., 1993) , is rich in lymphocytes. It has been regarded as an ideal route of immunization. However, orally administered naked DNA has little immunogenicity because of its easy decomposition during passage through the acidic environment of the stomach, so additional encapsulation would be necessary for oral administration. Several commercially available oral vaccines are based on live-attenuated organisms, such as vaccines against poliovirus, Vibrio cholerae and Salmonella typhi. Recently, mice immunized with attenuated Salmonella typhimurium delivering plasmid DNA encoding HBsAg by the oral route showed significantly stronger CTL responses than those receiving recombinant HBsAg vaccination, while comparable to i.m. immunization with naked DNA (Woo et al., 2001) . Nonetheless, the advantages of avoiding an antivector immune response may outweigh the increased efficiency of vector delivery.
In the current studies, we demonstrated that plasmid DNA encoding HBsAg encapsulated into PLGA microparticles induced local and systemic HBsAg-specific immunity following a single dose of oral immunization, combining the advantages of DNA vaccination with the ease of administration by the oral route and concomitant induction of mucosal immune responses. It was shown that the PLGA-DNA microparticle formulation not only augmented the immune responses, but also reduced the dose required for comparable responses to plasmid DNA in saline.
Our observations at day 14 post-administration of encapsulated DNA clearly showed that the sustained expression and presentation of target antigen correlated with our demonstration by RT-PCR that HBsAg mRNA was detectable in the draining lymph node under conditions where injection of naked DNA does not give detectable signal, providing direct evidence of immnopotentiation. Because extracellular DNA is rapidly degraded and cleared within hours after immunization (Singh et al., 2001; Lew et al., 1995) , the antigen-specific immune response to naked DNA may be dependent on the APCs present at the site of immunization. It seems reasonable to hypothesize that PLGA-DNA microparticles may promote immunity by acting as a means of prolonging the release of the plasmid DNA encoding the target antigen and preventing its degradation through encapsulation into a complex structure of polymeric material (Singh et al., 2004; Hedley, 2003) . The next investigation was to analyse quantitatively the proportion of APCs involved in expression and presentation of target antigen among total APCs in draining lymph nodes from immunized animals by flow-cytometry ) stably expressing HBsAg at 37 6C. After a 1-week in vitro culture, the specific cytolytic activity was tested in a non-radioactive and colorimetric assay against target cells. The E : T ratio was 100 : 1 in all of these assays. Values for specific lysis are from a representative experiment of three performed and are presented as mean±SD specific lysis of triplicate cultures, where n=8. detection using double immunolabelling with Abs against an APC marker and target antigen, providing direct evidence that PLGA-DNA microparticles directed delivery to APCs and facilitated uptake into APCs, reflecting the two advantages of the microparticle formulation: controlled release and target delivery (Singh et al., 2004; Hedley, 2003) .
Vaccination at mucosal surfaces may result in humoral and cellular responses, both systemic and local, the latter not only at the site of vaccination, but also at distant mucosal epithelia. This is a particularly important observation in relation to local and systemic HBsAg-specific immune responses including antibody and CTL responses, since it has previously been reported that oral immunization with a human papillomavirus 16 virus-like-particle vaccine (Nardelli-Haefliger et al., 2003) or live-attenuated typhoid vaccine Ty 21a (Kutteh et al., 2001) have been shown to be well tolerated, immunogenic and protective in women, inducing potent immune responses in the genital tract and other mucosa. Importantly, it has been reported that sexual transmission is one of the main routes of HBV infection, and a quarter of sexually transmitted HIV patients were infected simultaneously with HBV Kura et al., 1998) . Antibody and CTL responses in the genital mucosa play major roles in protection against sexual transmission of HIV-1 in humans (Garulli et al., 2004) . Subsequent studies using PLGA microparticles with encapsulated DNA will directly assess the ability of mucosal immunization to induce CTL responses in the genital mucosa. In this respect, the current observations of CTL responses in GALT following oral immunization with PLGA-DNA are very encouraging.
It was notable that the HBsAg-specific CTL activities elicited in our present study by a single immunization of PLGA-DNA microparticles were relatively low. It is unlikely that the current formulation is optimal. Therefore, further studies will be necessary to determine the effect of multiple doses and the kinetics of DNA delivery for an optimal vaccination protocol. New approaches, in particular promising prime-boost strategies of consecutive DNA priming followed by boosting with purified proteins, could be useful to improve the immunogenicity of these PLGA-DNA-based vaccines, as reported by Sharpe et al. (2003) .
In summary, this study describes the potential of oral DNA vaccination for induction of mucosal and systemic HBV HBsAg-specific cellular and humoral responses. The results may facilitate the development of a new type of protective HBV vaccine in humans.
